patient access
Czechia slams Germany over drug stockpiling
A German policy requiring pharmaceutical companies to hold six months worth of certain types of stock will squeeze other countries, says Czech deputy health minister.
Abortion rights activists rally voters for EU election
Denmark relaxes abortion law
Strong intellectual property is critical to competitive edge
Future of health: Time for Europe to connect the dots
Collaboration can unlock the potential of gene therapies in Europe
Speed is everything for patients: together we can bring medicines faster
Meet the moment: Don’t set back the clock on patients
A wave of concerning policies around the globe that are currently being implemented or are under discussion will, if the trend continues, have a profoundly negative impact on patients.
Taking medicines from bench to bedside
The ongoing review of the EU Pharmaceutical Legislation is looking at recalibrating IP incentives. Intellectual Property fuels medical innovations from the research bench to the patient’s bedside.
Is the EU falling behind in transforming lung cancer care?
Despite its pivotal role in the EU’s Beating Cancer Plan, patients have yet to fully benefit from next-generation sequencing. A groundbreaking report highlights what we can do to change this.
Campaigners sound conflict of interest alarm over MEP couple, missing pharma report
The romantic relationship between Pernille Weiss and Christian Ehler has raised questions about why an independent study was taken offline.
Elevating innovation through partnerships
Ricardo Marek, President Europe & Canada, Takeda Pharmaceuticals, shares these insights with POLITICO Studio.
Why we need to improve heart health in Europe
Despite progress, there is now an increase in the cardiovascular disease burden across all major European countries.
Beyond forgetfulness: Why we must act on Alzheimer’s disease now
Alzheimer’s disease is a ticking time bomb for individuals, families and health care systems, unless we invest in our future health today.
Labs: the (overlooked) building block of Universal Health Coverage
Universal Health Coverage may be high on the UNGA 78 health agenda, but will leaders back the diagnostics infrastructure that makes it possible?
Novo Nordisk’s weight-loss drug cuts heart failure symptoms
People treated with Wegovy had reduced physical limitations from heart failure and improved exercise function, the company said.
Pharma reform: Patients can’t afford to wait. Act now.
Waiting five years to try and fix patient access while we watch EU competitiveness decline is not the solution.
Benefits of the Substances of Human Origin (SoHO) Regulation
How the SoHO Regulation can increase plasma collection and improve donor health.
Putting health back in health care
Opportunity for equity: The WHO Resolution on diagnostics capacity.
Optimizing plasma collection and donor safety
The Substances of Human Origin Regulation has potential to increase patient access to plasma-derived medicines.
Scholz’s China visit secures BioNTech/Pfizer vaccine access for expats
German chancellor says this would be a ‘first step’ toward wider use of the vaccine.
Europe’s leadership in life sciences needs strong frameworks and partnerships
POLITICO Studio speaks with Ricardo Marek, President Europe and Canada at Takeda Pharmaceuticals, on why rare diseases need to be a public health priority, and how Europe can remain a leader in life sciences.
Unlocking the potential of biosimilars to enable sustainability of European health care systems
In conversation with Dan Cohen, vice president and head of the Biosimilars Unit for Europe, Canada and partner markets at Biogen.
Unlocking the potential of biosimilars for more sustainable care
Biosimilars, or alternatives to licensed biological therapies, can increase access to treatment and alleviate financial burdens on health care systems.
EU stonewalls over von der Leyen’s role in multibillion-euro Pfizer vaccine deal
European Court of Auditors accuses Commission of refusing to release details of how the bloc’s biggest vaccine contract was negotiated.
Building Europe’s gene therapy ecosystem
Europe has led the way in developing the science of gene therapy. Now the continent needs to bring flexibility into its health systems to move from lab to reality.
Why does innovation in Europe matter to patients?
We have never had as many medicines in development as we do today. But how can this potential be realized for patients, how can Europe step up to the challenge?
Europe’s growing abortion nightmare
Even in the absence of a ban, for women in need of abortion access, the overall picture is grim — and the worst is yet to come.